Patents Examined by Elizabeth C. Weimar
  • Patent number: 5604204
    Abstract: A method is provided for generation of bone at a site of an animal where skeletal tissue is deficient comprising administering to the animal, locally at the bone site in the presence of a source of osteogenic cells, an effective amount of a composition comprising TGF-.beta. in a pharmaceutically acceptable carrier, provided that such composition excludes a bone morphogenetic cofactor, the composition being administered in an amount effective to induce bone growth at the bone site. Also provided is a device for implantation into a site of an animal where skeletal tissue is deficient comprising a device treated with an effective amount of a composition comprising TGF-.beta. and a source of osteogenic cells in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: February 27, 1995
    Date of Patent: February 18, 1997
    Assignee: Genentech, Inc.
    Inventors: Arthur J. Ammann, Christopher G. Rudman
  • Patent number: 5602207
    Abstract: A solid support and method for immobilization and sequence analysis of polypeptides. In one aspect, the invention is directed to a method for immobilizing a polypeptide on a solid support. In the method, a solid support having surface-attached carboxylic acid groups is reacted with an isoxazolium salt to form an activated support. After the activated support has been washed to remove residual isoxazolium salt and base, the support is dried. The dried support is then contacted with a polypeptide under conditions effective to bind the polypeptide covalently to the support. The immobilized polypeptide can be conveniently sequenced by N- and C-terminal sequencing methods.
    Type: Grant
    Filed: September 29, 1993
    Date of Patent: February 11, 1997
    Assignee: The Perkin-Elmer Corporation
    Inventors: Victoria L. Boyd, Pau-Miau Yuan
  • Patent number: 5602102
    Abstract: Therapeutic agents and methods for the treatment of immunologically mediated diseases and malignancies of myeloid cell or lymphoid cell origin. These particular methods utilize the characterization of particular activation mechanisms important to the progression of these pathologies in humans. Selective inhibition of cell types responsible for precipitating these disorders in humans are provided with therapeutic agents which include peptides capable of inhibiting dipeptidyl peptidase-I activation of proenzymes present primarily in cytotoxic T-cells and myeloid cells, such as Gly--Phe--CHN.sub.2. Antisense oligonucleotides are also characterized which are specific for human dipeptidyl peptidase-I gene which may be used in the treatment of the described disorders.
    Type: Grant
    Filed: May 29, 1992
    Date of Patent: February 11, 1997
    Assignee: Board of Regents, The Univ. of TX System
    Inventors: Dwain L. Thiele, Peter E. Lipsky, Michael J. McGuire
  • Patent number: 5595823
    Abstract: A fuser member useful for heat-fixing an electrographic toner to a substrate. The fuser member has a core and a layer overlying the core. That layer includes a cured fluorocarbon random copolymer having subunits with the general structures: ##STR1## where x is from 30 to 90 mole percent, y is from 10 to 70 mole percent, and z is from 0 to 34 mole percent. The layer incorporates particulate filler. The filler includes aluminum oxide and a material selected from the group consisting of alkali metal oxides, alkali metal hydroxides, and combinations thereof. The filler has a total concentration in the layer of from about 25 to 50 percent of the total volume of the layer. The aluminum oxide has a concentration of from 20 to 40 percent of the total volume of the layer.
    Type: Grant
    Filed: June 29, 1994
    Date of Patent: January 21, 1997
    Assignee: Eastman Kodak Company
    Inventors: Jiann H. Chen, John J. Fitzgerald, William B. Vreeland, II, Wayne T. Ferrar, Gary F. Roberts, William J. Staudenmayer
  • Patent number: 5595971
    Abstract: Prolonged parenteral release of a bioactive polypeptide at desirably effective levels can be achieved using novel compositions in which the polypeptide is present in a biocompatible oil in an unusually high proportion such as at least about 10% by weight. Also disclosed are certain metal-associated somatotropins that are useful for prolonged parenteral release of such somatotropins.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: January 21, 1997
    Assignee: Monsanto Company
    Inventor: James W. Mitchell
  • Patent number: 5593666
    Abstract: A method and composition utilizing thrombopoietin for increasing platelet cell counts in thrombocytopenia is disclosed. The method and composition are suitable for treatments of patients suffering from medical conditions, such as HIV/AIDS or chemotherapy, which result in low platelet cell numbers. Also disclosed are the active moieties or domains of the thrombopoietin molecule.
    Type: Grant
    Filed: October 27, 1994
    Date of Patent: January 14, 1997
    Assignee: The University of Tennessee Research Corp.
    Inventor: Ted P. McDonald
  • Patent number: 5593966
    Abstract: Peptide derivatives with inhibitory activity on the enzyme systems involved in the oxidative burst of human phagocytic cells comprise six and seven amino acid peptide sequences from human cytochrome b.sub.558. The derivatives may be used in medicaments for the treatment of inflammatory diseases.
    Type: Grant
    Filed: May 24, 1990
    Date of Patent: January 14, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Harry L. Malech, Daniel Rotrosen
  • Patent number: 5594110
    Abstract: A conjugate of an antiviral nucleoside with a lactosaminated human albumin (L-HSA) and its method of preparation is described. The method of preparation involves the reaction of an antiviral phosphorylated nucleoside in the form of an imidizolide with L-HSA at a pH above 7.5 and running the reaction until the desired molar ratio of drug to L-HSA is obtained.
    Type: Grant
    Filed: September 30, 1994
    Date of Patent: January 14, 1997
    Assignee: Laboratori Baldacci SpA
    Inventors: Luigi Fiume, Corrado Busi, Giuseppina D. Stefano, Alessandro Mattioli
  • Patent number: 5594104
    Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: January 14, 1997
    Assignee: Eli Lilly and Company
    Inventors: Margret B. Basinski, Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, Brigitte E. Schoner, James E. Shields, David L. Smiley
  • Patent number: 5594101
    Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: March 3, 1995
    Date of Patent: January 14, 1997
    Assignee: Eli Lilly and Company
    Inventors: Gerald W. Becker, John E. Hale, Warren C. MacKellar
  • Patent number: 5593967
    Abstract: Novel cholecystokinin antagonists useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further, the compounds are antianxiety agents and antiulcer agents. They are agents useful for preventing the response to the withdrawal from chronic treatment with use of nicotine, diazepam, alcohol, cocaine, coffee, or opioids. The compounds of the invention are also useful in treating and/or preventing panic. Also disclosed are pharmaceutical compositions and methods of treatment using the antagonists as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds in diagnostic compositions.
    Type: Grant
    Filed: April 1, 1993
    Date of Patent: January 14, 1997
    Assignee: Warner-Lambert Company
    Inventors: David C. Horwell, Edward Roberts, Ann Holmes, Janak K. Padia, William H. Roark, Bruce D. Roth, Bharat K. Trivedi, Jurgen Kleinschroth, David C. Rees, Reginald S. Richardson
  • Patent number: 5594112
    Abstract: Acridinium compounds represented by the general formula (I) where A is an intervening group which does not have activity for binding with a specific binding substance, Z is a labelling active group which has activity for binding with a specific binding substance, R.sup.1 is a halogen atom, an alkyl group or an aryl group; R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are each a hydrogen atom, an alkyl group, an aryl group, an alkoxy group, a nitro group, a halogen atom or a carbonyl group, and Y is a counter ion. The acridinium compounds may form conjugates with specific binding substances. The acridinium compounds have high emission efficiency and stability and, hence, are useful as chemiluminescence labelling agents.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: January 14, 1997
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Naofumi Sato, Hiroshi Mochizuki, Toshinori Kanamori
  • Patent number: 5591719
    Abstract: A method for treating acute or chronic inflammatory or autoimmune disorders using polypeptides with fibronectin or related activity is provided. The method involves (administering an amount of) one or more polypeptides corresponding to isolated amino acid residue sequences of the 33 kD carboxy terminal heparin-binding region located on the A chain of fibronectin to effectively suppress inflammation and impairment of tissue function in a patient.
    Type: Grant
    Filed: December 10, 1992
    Date of Patent: January 7, 1997
    Assignees: Regents of the University of Minnesota, The United States of America as represented by the Secretary of Health and Human Services
    Inventors: Leo T. Furcht, James B. McCarthy, Sharon M. Wahl, Janice B. Allen
  • Patent number: 5591821
    Abstract: The present invention is directed to .omega.-conotoxin peptides having 24-30 amino acids, six cysteines which form disulfide bonds between the first and fourth, second and fifth, and third and sixth cysteines, respectively, and an internal sequence of Cys-Arg-Lys-Thr-Xaa.sub.1 -Tyr-Xaa.sub.2 -Cys-Cys-Ser-Gly-Ser-Cys (SEQ ID NO:1). The invention is further directed to .omega.-conotoxin peptides of the generic formula Cys-Xaa.sub.1 -Gly-Xaa.sub.2 -Gly-Ala-Xaa.sub.3 -Cys-Arg-Lys-Thr-Xaa.sub.4 -Tyr-Xaa.sub.5 -Cys-Cys-Ser-Gly-Ser-Cys-Xaa.sub.6 -Arg-Gly-Xaa.sub.7 -Cys (SEQ ID NO:2). Preferably, the C-terminus is amidated. These peptides also contain three disulfide bonds. Examples of .omega.-conotoxin peptides within the generic formula are MVIIC having the formula Cys-Cys-Gly-Lys-Gly-Ala-Xaa.sub.1 -Cys-Arg-Lys-Thr-Xaa.sub.2 -Tyr-Asp-Cys-Cys-Ser-Gly-Ser-Cys-Gly-Arg-Arg-Gly-Lys-Cys (SEQ ID NO:3), wherein Xaa is preferably Pro or Hyp (4-hydroxyproline) and Xaa.sub.
    Type: Grant
    Filed: July 16, 1993
    Date of Patent: January 7, 1997
    Assignee: The University of Utah
    Inventors: Baldomero M. Olivera, David R. Hillyard, Julita S. Imperial, Virginia D. Monje
  • Patent number: 5587457
    Abstract: The present invention provides peptides capable of stimulating neutrophils. In particular, the peptides prime neutrophils for a respiratory burst following treatment with N-formyl-L-methionyl-L-leucyl-Lphenylalanine. The peptides have an amino acid sequence substantially corresponding to amino acids 54 to 94 of FIG. 1 or a part thereof. These peptides may also be used in the treatment of a subject having depressed neutrophil function.
    Type: Grant
    Filed: August 16, 1993
    Date of Patent: December 24, 1996
    Assignee: Peptide Technology Limited
    Inventors: Deborah A. Rathjen, Antonio Ferrante
  • Patent number: 5587444
    Abstract: A novel copolymer affording a highly efficient electroluminescent element by the use of which the movement of electric charge occurs very efficiently and a full color luminescence is possible, a process for producing the same and an electroluminescent element, are provided, which copolymer is prepared by copolymerizing N-vinylcarbazole as an electron-transporting compound with a specified cumarin derivative as a luminescent compound; which process comprises copolymerizing a specified quantity of a specified cumarin derivative with a specified quantity of N-vinylcarbazole in the presence of a polymerization initiator or a catalyst; and which electroluminescent element is prepared by using a thin film obtained from the copolymer.
    Type: Grant
    Filed: December 27, 1994
    Date of Patent: December 24, 1996
    Assignee: Chisso Corporation
    Inventors: Manabu Uchida, Takenori Izumizawa, Kenji Furukawa
  • Patent number: 5585353
    Abstract: Antibiotically and/or antimalarially active D-peptides of naturally occurring antibiotics such as cecropin A, B and D, melittin, and Magainin I and II and their addition, deletion and replacement analogs including homologous and heterologous analogs thereof.
    Type: Grant
    Filed: September 16, 1994
    Date of Patent: December 17, 1996
    Assignee: The Rockefeller University
    Inventors: Robert B. Merrifield, David Wade, Hans G. Boman
  • Patent number: 5585349
    Abstract: The invention provides a method of treating a viral infection in a mammal comprising administering an effective amount of modified C-reactive protein (CRP) to the mammal. In particular, modified-CRP has been found to be effective and safe for treating retroviral infections, including human immunodeficiency virus 1. The invention also provides a method of neutralizing a virus comprising contacting the virus with modified-CRP. In particular, modified-CRP can be used to neutralize viruses in blood which is to be used for transfusions by adding the modified-CRP to the blood prior to the transfusion.
    Type: Grant
    Filed: September 7, 1993
    Date of Patent: December 17, 1996
    Assignee: Immtech International, Inc.
    Inventor: Lawrence A. Potempa
  • Patent number: 5585346
    Abstract: Peptide derivatives with inhibitory activity on the enzyme systems involved in the oxidative burst of human phagocytic cells comprise a certain sequence of a number of carboxyl-terminal amino acids of human cytochrome b.sub.558. The derivatives may be used in medicaments for the treatment of inflammatory diseases.
    Type: Grant
    Filed: March 31, 1989
    Date of Patent: December 17, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Harry L. Malech, Karen J. Lomax, Daniel Rotrosen, Hiroyuki Nunoi
  • Patent number: 5583114
    Abstract: This invention is related to an adhesive composition which may be used to bond or seal tissue in vivo. The adhesive composition is readily formed from a two component mixture which includes a first part of a protein, preferably a serum albumin protein, in an aqueous buffer having a pH in the range of about 8.0-11.0 and a second part of a water-compatible or water-soluble bifunctional crosslinking agent. When the two parts of the mixture are combined, the mixture is initially a liquid which cures in vivo on the surface of tissue in less than about one minute to give a strong, flexible, pliant substantive composition which bonds to the tissue and is absorbed in about four to sixty days. The adhesive composition may be used either to bond tissue, to seal tissue or to prevent tissue adhesions caused by surgery.
    Type: Grant
    Filed: July 27, 1994
    Date of Patent: December 10, 1996
    Assignee: Minnesota Mining and Manufacturing Company
    Inventors: Thomas H. Barrows, Terry W. Lewis, Myhanh T. Truong